Methotrexate (MTX) is an immunosuppressant commonly used for the treatment of autoimmune diseases. Recent observations have shown that patients treated with MTX also exhibit a reduced risk for the development of cardiovascular disease (CVD). Although MTX reduces systemic inflammation and tissue damage, the mechanisms by which MTX exerts these beneficial effects are not entirely known. We have previously demonstrated that protein adducts formed by the interaction of malondialdehyde (MDA) and acetaldehyde (AA), known as MAAprotein adducts, are present in diseased tissues of individuals with rheumatoid arthritis (RA) or CVD. In previously reported studies, MAA-adducts were shown to be highly immunogenic, supporting the concept that MAA-adducts not only serve as markers of oxidative stress but may have a direct role in the pathogenesis of inflammatory diseases. Because MAA-adducts are commonly detected in diseased tissues and are proposed to mitigate disease progression in both RA and CVD, we tested the hypothesis that MTX inhibits the generation of MAA-protein adducts by scavenging reactive oxygen species. Using a cell free system, we found that MTX reduces MAA-adduct formation by approximately 6-fold, and scavenges free radicals produced during MAA-adduct formation. Further investigation revealed that MTX directly scavenges superoxide, but not hydrogen peroxide. Additionally, using the Nrf2/ARE luciferase reporter cell line, which responds to intracellular redox changes, we observed that MTX inhibits the activation of Nrf2 in cells treated with MDA and AA. These studies define previously unrecognized mechanisms by which MTX can reduce inflammation and subsequent tissue damage, namely, scavenging free radicals, reducing oxidative stress, and inhibiting MAA-adduct formation. http://dx.
Introduction
Methotrexate (MTX) is a cornerstone treatment of a number of autoimmune diseases such as rheumatoid arthritis (RA) and psoriasis, diseases characterized by a state of chronic inflammation. Although MTX reduces markers of inflammation, the mechanism(s) by which it exerts these effects is not well understood. Clinically, the treatment of RA patients with MTX has been shown to be effective in reducing the risk of cardiovascular events by 21% compared with other disease-modifying antirheumatic drugs (DMARDs) [1] . Others have demonstrated MTX use to be associated with a 70% reduction in CVD-mortality risk among those with RA [2] . Similar to RA, cardiovascular disease (CVD) is also well-recognized as a chronic inflammatory disease [3] [4] [5] [6] . In fact, the beneficial effects of MTX in RA-associated CVD has led to the funding and implementation of the Cardiovascular Inflammation Reduction Trial (CIRT) [7] . In the CIRT, investigators are testing the hypothesis that low-dose MTX reduces rates of myocardial infarction, stroke, and cardiovascular death among stable coronary artery disease patients with type 2 diabetes or metabolic syndrome, conditions associated with enhanced pro-inflammatory responses [7, 8] .
Modified lipoproteins are thought to be important to the development and progression of CVD [9] [10] [11] [12] . Accumulation of these modified lipoproteins creates and maintains a state of chronic inflammation, which results in progressive oxidative stress and lipid peroxidation. Two by-products of lipid peroxidation are malondialdehyde (MDA) and acetaldehyde (AA) [13] . These two highly reactive aldehydes can interact to covalently modify biomolecules, including proteins and lipoproteins, forming highly stable adducts referred to as malondialdehydeacetaldehyde (MAA)-adducts [3, [14] [15] [16] . MAA-adducted proteins have been detected in atherosclerotic plaques [9] , as well as in the synovial tissues of individuals suffering from RA [17] . Importantly, MAA-adducts have been shown to be pro-inflammatory [18] [19] [20] , and as such may play a key pathogenic role in the initiation and development of the sterile inflammation associated with both RA and CVD.
Because MTX demonstrates clinical benefit in the treatment of both RA and CVD, we initiated studies to determine if there was a common mechanism by which MTX ameliorated these conditions. Common pathologic characteristics among CVD and RA include chronic inflammation, MAA-adduct production, and an increase in reactive oxygen species (ROS). Therefore, we tested the hypothesis that MTX inhibits the formation of MAA-protein adducts and decreases levels of ROS.
We found that MTX inhibits the formation of MAA-adducts and that the decrease in MAA-adduct formation is mediated by the ability of MTX to directly scavenge free radicals, particularly superoxide (O 2
•-).
These findings not only help to explain possible mechanism(s) by which MTX reduces the health burden posed by CVD and RA, but also suggest that compounds such as MTX that specifically scavenge O 2 •may be beneficial in the treatment of other diseases in which chronic inflammation and elevated levels of ROS have important pathological roles.
Materials and methods

Malondialdehyde-Acetaldehyde (MAA)-protein adduct formation
Malondialdehyde-acetaldehyde-adducted human serum albumin (MAA-ALB) was created by reacting 1 mg/ml of pharmaceutical grade ALB (Talecris Biotherapeutics Inc., Research Triangle Park, NC) with 2 mM MDA, and1 mM AA, in phosphate-buffered saline (PBS), for 24, 48 or 72 h at 37°C as previously described [13] . To determine the effectiveness of MTX at reducing the formation of MAA-ALB, varying concentrations of MTX (1-10 μM) (Hospira Inc., Australia) (data not shown) were added to the ALB + MDA + AA reaction. Formation of MAA-ALB was monitored by its auto-fluorescence (excitation 398 nm and emission 460 nm) in a Turner Biosystems (Sunnyvale, CA) LS-5B spectrofluorometer as previously described [13] . Two μM MTX was determined to be the minimal effective dose of MTX to inhibit MAA-ALB formation and was used throughout the study.
Electron Paramagnetic Resonance (EPR) Spectroscopy
To determine if the reaction of ALB + MDA + AA and formation of MAA-ALB, produced free radicals, we utilized Electron Paramagnetic Resonance (EPR) Spectroscopy to measure levels of free radicals in 1 ml cell-free reactions containing 1 mg ALB, 2 mM MDA, and 1 mM AA. To examine the ability of MTX to scavenge free radicals that might be generated, a subset of samples contained 2 µM MTX. Control samples contained ALB alone in vehicle (i.e. PBS). Reactions were incubated for 24, 48, or 72 h at 37°C, after which 200 µM of the EPR spin probe, 1hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethylpyrrolidine (CMH), was added to all reactions for 30 min at 37°C. Fifty μl of the sample was then loaded into a glass capillary tube and inserted into the capillary holder of a Bruker e-scan EPR spectrometer. Upon reacting with free radicals, such as superoxide (O 2
•-), the CMH spin probe becomes a stable nitroxide radical, which when placed in the appropriate magnetic field scan (Gauss) at 37°C yields a characteristic 3-peak EPR spectrum [21] . The amplitude of the EPR spectrum is directly proportional to the level of free radicals in the sample [21] . The following EPR spectrometer settings were used for these and all experiments described below: field sweep width, 60.0 G; microwave frequency, 9.74 [22] . In KDD (+) buffer, HRP + AAP mediate the H 2 O 2 -dependent oxidation of CMH to the stable nitroxide radical [23] . Catalase, a well-known direct scavenger of H 2 O 2 , was used to corroborate the fidelity of this assay. Samples were incubated at 37°C for 30 min and EPR spectra were obtained, as described above.
Xanthine oxidase activity
To ensure that MTX did not interfere with the ability of xanthine oxidase (XO) to produce of O 2
•and uric acid, the activity of XO was determined by spectrophotometrically measuring levels of uric acid as previously described [24] . Cell-free reactions containing HX (50 µM) and XO (10 mU/ml) in the absence or presence of 2 µM MTX were placed into a SpectraMax M5e Microplate Reader and the absorbance of uric acid at 292 nm was recorded every 5 min for 30 min.
Cellular redox signaling
To determine if MTX influences intracellular redox signaling pathways activated by the generation of MAA-adducted protein (i.e. ALB), we utilized a nuclear factor (erythroid derived 2)-like 2/antioxidant response element (Nrf2/ARE) luciferase reporter cell line (HEK293; Signosis, Inc., Santa Clara, CA). In these cells, redox-dependent stabilization of Nrf2 results in the translocation of this transcription factor to the nucleus where it binds to its antioxidant response element (ARE) promoter region, which is upstream of the firefly luciferase coding region. As such, stabilization and activation of Nrf2 results in an increase in luciferase expression, which was assayed by measuring luminescence with a Turner Biosystems (Sunnyvale, CA) LS-5B luminometer.
Cells were grown to confluency and incubated with ALB + vehicle, 2 mM MDA + 1 mM AA, or 1 mg/ml ALB + 2 mM MDA + 1 mM AA in the presence or absence of 2 µM MTX for 24 h. Following incubation, the media was aspirated and replaced with PBS. As recommended by the manufacturer (Promega, Madison, WI), a passive lysis buffer was added to the cells followed by a luciferase substrate (Signosis) and luminescence was measured. Studies were performed to determine if previously modified MAA-ALB (incubated 3 days) would induce oxidative stress in the NRF2/ARE cell line. Cells were incubated with vehicle or MAA-ALB (25 µg/ml) in the presence or absence of 2 µM MTX for 24 h. Luminescence was determined as described above.
Cell viability
A cell viability assay measuring lactate dehydrogenase (LDH), per manufacturer protocol (Roche, Germany), was used to determine the viability of the Nrf2/ARE cells treated with ALB + vehicle, ALB + MDA + AA, ALB + MDA + AA + MTX (ALB: 1 mg; MDA: 2 mM; AA 1 mM; MTX: 2 µM), or pre-formed MAA-ALB for 24 h. Data was collected, viability calculated, and is presented as percent viability over 24 h.
Statistical analysis
All of the data are expressed as mean ± SEM. Statistical analysis was performed using Sigma Plot 10.0 with SigmaStat (Jandel Scientific, 2006) or GraphPad Prism. Significance was assessed using one-way or multiple ANOVA with Bonferroni's multiple comparisons test where appropriate. Differences were considered statistically significant at p < 0.05.
Results
Methotrexate inhibits the formation of MAA-protein adducts
We have recently reported MAA-adducted proteins are present in the diseased tissue of individuals with RA and CVD, both diseases in which treatment with MTX reduces the progression of the disease [17, 25] . Because of this, we speculated that MTX may inhibit the formation of MAA-protein adducts. Therefore, we examined the ability of MTX to influence the generation of MAA-protein adducts formed as a consequence of chronic inflammation during oxidative stress.
To form MAA-protein adducts in vitro, MDA and AA in a 2:1 M ratio were incubated with ALB in a cell-free reaction and MAA-ALB formation was monitored by measuring the fluorescence of its dihydropryridine ring structure. As shown in Fig. 1, after 24 , 48, and 72 h, this reaction yielded an increase in MAA-adducted ALB compared to control samples (ALB + vehicle). Interestingly, the formation of MAA-ALB was significantly attenuated in reactions containing MTX ( Fig. 1 ).
Methotrexate decreases free radicals produced during the generation of MAA-adducts
Because MAA-protein adducts form as a result of oxidative stress and the resulting post-translational modifications [13] , and MTX inhibits this process ( Fig. 1) , we investigated the ability of MTX to decrease levels of free radicals (i.e. molecules with an unpaired electron) produced during the formation of MAA-protein adducts. Free radicals were measured by EPR spectroscopy, the gold-standard for detecting free radicals, such as O 2
•-. Compared to control samples of ALB alone, the reaction of MDA + AA + ALB for 24, 48, and 72 h produced a robust increase in free radical levels, as exhibited by an increase in the EPR spectrum amplitude obtained from these samples (Fig. 2) . Addition of MTX to samples containing MDA + AA + ALB, markedly attenuated the increase in EPR spectrum amplitude (Fig. 2) . These data indicate that MTX directly scavenges free radicals produced during the generation of MAA-ALB.
Methotrexate directly scavenges superoxide
To further demonstrate that MTX directly scavenges free radicals, we utilized cell-free reactions of HX and XO to generate O 2
•and measured O 2 •levels, using EPR spectroscopy, in the absence or presence of MTX. Concentration-response curves of both HX (1-50 µM) and XO (1-50 mU/ml) were conducted to determine the ideal concentrations of HX and XO needed to generate EPR spectroscopy-detectable levels of O 2 •-(Supplemental Fig. 1 ). Using 50 µM HX and 10 mU/ml of XO, we observed a significant increase in the EPR spectrum amplitude (Fig. 3A, B) (Fig. 4) . Notably, 10 mM MTX failed to scavenge H 2 O 2 , which is two times the highest concentration of MTX that significantly scavenged O 2 •- (Fig. 3 ) 
MAA-protein adduct-induced intracellular redox signaling is attenuated by MTX
To extend our observations in cell-free reactions that MTX acts as an antioxidant by directly scavenging O 2
•-, we utilized a cell culture model in which activation of the redox-sensitive transcription factor, Nrf2, can be easily determined. In the Nrf2/ARE cells, increases in intracellular ROS and subsequent changes in the redox environment to a more oxidative state results in the stabilization of Nrf2, allowing it to translocate to the nucleus where it binds to the ARE promoter region and drives the expression of luciferase. Incubating Nrf2/ARE cells with MDA and AA ± ALB for 24 h significantly increased luciferase expression, as determined by an increase in luminescence (Fig. 5A ). This redox-dependent response was significantly attenuated by MTX ( Fig. 5A) , indicating that the elevated levels of intracellular free radicals induced by MDA and AA ± ALB are scavenged by MTX. Furthermore, incubation of the Nrf2/ARE cells with previously modified MAA-ALB (25 µg/ml) did not increase luciferase expression ( Fig. 5A) and 2) are necessary for Nrf2/ARE activation. Importantly, MDA and AA ± ALB in the absence or presence of MTX did not alter cell viability, nor did pre-formed MAA-ALB (Fig. 5B ). Collectively, these data indicate that MDA and AA ± ALB but not previously modified MAA-ALB increases intracellular free radicals leading to the activation of redox signaling pathways, which are inhibited by MTX.
Discussion
Inflammation is a critical component of numerous chronic diseases including CVD and RA. Recruitment and activation of inflammatory cells increases the production of free radicals. Free radicals can react with lipids producing lipid peroxides. As a result of lipid peroxidation, reactive aldehydes such as MDA and AA are formed. These reactive aldehydes can interact with biomolecules forming MAA-adducts. Because of this sequence of reactions MAA-adducted molecules, such as proteins, are likely present at sites of inflammation. We have shown that MAA-adducted proteins can elicit potent pro-inflammatory immune responses [18] [19] [20] . As such, MAA-adducted proteins may not only be present in diseased tissues but may also directly contribute to and perpetuate local inflammation, ultimately leading to a chronic inflammatory state. We have shown that MAA-adducted proteins are localized in atheromatous lesions [9] as well as synovial tissues in RA [17, 25] . Recognizing that both of these conditions are characterized by chronic inflammation, suppressing local MAA-adduct production and the corresponding reduction in MAA-specific inflammatory responses could conceivably attenuate the severity of the disease.
MTX is a cornerstone treatment for RA and is actively being accessed in at least one large clinical trial for the secondary prevention of atherosclerosis and myocardial events [7] . The rationale for the clinical use of MTX in cardiovascular disease stems from observations that patients with RA undergoing treatment with MTX have a marked reduction in the incidence of myocardial events [1] . Despite the unquestionable clinical utility of MTX, the exact mechanism(s) by which it reduces the risk and severity of these diseases is not clear. The mechanisms of MTX as a DMARD in the treatment of RA, although not completely understood, are thought to result from the inhibition of interleukin-1β (IL-1β), interleukin 1 receptor antagonism, inhibition of interleukin-6 (IL-6), and/or inhibition of tumor necrosis factor-α (TNFα) [26, 27] . Alternatively, it has been proposed that MTX derives its anti-inflammatory actions by indirectly increasing the extracellular levels of adenosine, a well-known regulator of inflammation and immune responses [28, 29] . The current study identifies previously unrecognized actions of MTX, including the inhibition of MAA-adduction and the direct scavenging of free radicals, particularly O 2
The formation of stable MAA-adducts such as MAA-ALB, occurs when proteins are exposed to both MDA and AA [13] . Importantly, MAA-adducts have been detected in atherosclerotic lesions from CVD patients and synovial tissues of RA patients. In contrast, MAA-adducts are undetectable in normal vascular tissues or in synovial tissue from patients with non-inflammatory (i.e. osteoarthritis) arthritis [9, 17] . Additionally, increased levels of circulating anti-MAA antibody are present in patients with both CVD and RA. Because MAA-adducts are present at the sites of tissue damage and promote inflammatory responses, they may have a critical role in the development and progression of chronic inflammatory diseases.
Recognizing that MAA-adduction occurs via an SN2 reaction (a nonenzymatic nucleophilic substitution) [30] [31] [32] and MTX is a potential SN2 substrate, we tested the possibility that MTX would inhibit the formation of MAA-adducted proteins. Specifically, co-incubation of ALB, MDA and AA with MTX resulted in approximately a 6-fold reduction in the MAA-adduction of ALB. Furthermore, addition of MTX to the ALB, MDA, and AA reaction resulted in reduced levels of free radicals. Additional studies employing the well described O 2 •producing system XO and HX demonstrated that MTX directly scavenges O 2
•-
, but not hydrogen peroxide. Thus, the ability to scavenge O 2
•appears to be a mechanism by which MTX inhibits the formation of MAA-adducts. The inhibition of MAA adduct formation and scavenging of free radicals may reduce the inflammation associated with CVD and RA, thereby reducing tissue damage. In addition to determining the effects of MTX in cell free systems, we investigated its possible biological utility using the luciferase-based reporter cell line Nrf2/ARE. These cells respond to heightened levels of free radicals by stabilizing the redox-sensitive transcription factor Nrf2, which then translocates to the nucleus and binds the ARE in the promoter upstream of the luciferase coding region. Addition of MDA, AA, and ALB to the growth media of these cells induced intracellular redox signaling and the expression of luciferase. Interestingly, incubating the cells with free MDA and AA in the absence of ALB also resulted in increased redox signaling and expression of luciferase. Importantly, addition of MTX attenuated the increase in redox signaling, and decreased luciferase expression both in the absence or presence of ALB. In contrast, incubating the Nrf2/ARE cells with previously modified MAA-ALB without free MDA or AA did not increase the expression of luciferase. These findings indicate that in the Nrf2/ARE cells free MDA and AA, rather than the presence of pre-formed MAA-adducts, are required for the production of free radicals and the resulting redox signaling.
Proteins modified by adducts such as MAA bind and are internalized by a family of cell surface receptors known as scavenger receptors [33, 34] . The Nrf2/ARE cells used in these studies are based on HEK cells, which do not express scavenger receptors. Because of this, the potential effects of binding and internalization of MAA-ALB was not addressed in these studies. Although not investigated in these studies, we propose that it is possible that binding of MAA-adducted proteins to cell surface scavenger receptors results in ROS production, lipid peroxidation, inflammation, and the formation of intracellular MDA and AA. The free intracellular MDA and AA may bind endogenous substrates forming intracellular MAA-adducts, that upon release/secretion from cells may bind to scavenger receptors on the surface of other cells perpetuating the process and amplifying inflammation.
In summary, we have defined a previously undescribed mechanism by which MTX can reduce inflammation. MTX directly scavenges O 2
, inhibits the formation of MAA-adducts, scavenges free radicals associated with MAA-adduction, and attenuates intracellular oxidative stress. We propose that by scavenging free radicals including O 2
•and reducing the formation of MAA-adducts, subsequent inflammatory responses are reduced and tissue damage is mitigated.
